PYC Therapeutics Limited (PH7.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
As of 09:08AM CEST. Market open.
| Previous Close | 0.0890 |
| Open | 0.0890 |
| Bid | 0.0000 x 200000000 |
| Ask | 0.0000 x 8333400 |
| Day's Range | 0.0890 - 0.0890 |
| 52 Week Range | 0.0671 - 0.1200 |
| Volume | |
| Avg. Volume | 932 |
| Market Cap | 295.633M |
| Beta (5Y Monthly) | 0.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0040 |
| Earnings Date | Jul 23, 2024 - Jul 28, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Simply Wall St.Here's Why We're Not Too Worried About PYC Therapeutics' (ASX:PYC) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
PR NewswirePYC'S FOURTH DRUG CANDIDATE HAS DISEASE-MODIFYING POTENTIAL IN POLYCYSTIC KIDNEY DISEASE
PYC Therapeutics today announces the results of a study conducted in human 3-dimensional models derived from patients with end-stage renal failure due to Autosomal Dominant Polycystic Kidney Disease (PKD). The results demonstrate that an investigational drug candidate designed by PYC (known as PYC-003) to address this disease at its root cause is effective. These 3D patient-derived cyst models represent the 'gold-standard' pre-clinical assay for evaluating drug candidates in this indication[8].
© 2024 Yahoo. All rights reserved.